echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Promising to be the first eye drops for the treatment of presbyopia, AbbVie's innovative treatment phase 3 clinical results are positive

    Promising to be the first eye drops for the treatment of presbyopia, AbbVie's innovative treatment phase 3 clinical results are positive

    • Last Update: 2021-07-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, Allergan, a subsidiary of AbbVie, announced the complete results of the research treatment AGN-190584 (pilocarpine 1.


    Presbyopia affects nearly 2 billion people worldwide, and there are currently no effective drug solutions available for patients


    AGN-190584 is an innovative and optimized ophthalmic formula of pilocarpine


    The GEMINI 1 trial evaluated the efficacy and safety of AGN-190584 in 323 participants


    Based on the results of GEMINI 1 and GEMINI 2, AbbVie has submitted a New Drug Application (NDA) for AGN-190584 to the US FDA


    Note: The original text has been deleted

    Reference materials:

    [1] New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.